SCYNEXIS Inc

SCYNEXIS CEO Buys Shares Amid $100M Private Placement: What Investors Should Know

SCYNEXIS CEO buys shares during $100 M private placement – signals confidence yet raises dilution risk as the firm targets rare fungal and kidney disease trials.

SCYNEXIS Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

02/04/2026, 18:22

4 minutes to read

CEO’s Insider Buy Signals SCYNEXIS’s Strong Orphan‑Drug Upside

Insider buying signals confidence in SCYNEXIS’s orphan‑drug strategy, highlighting CEO‑led equity stake, Phase 2 milestones, and high‑pricing potential.

SCYNEXIS Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

02/04/2026, 14:17

4 minutes to read